/
LNAI
$2.26-$0.11 (-4.68%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$10.7M
5M shares
52-week range
$1.21 – $13.28
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-8.00
Lunai Bioworks Inc. Common Stock
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
www.renovarogroup.com- Employees
- 29
- IPO / List date
- Nov 18, 2014
- HQ
- SUITE 906 LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds LNAI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LNAI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-22 | 1-for-8reverse |
| 2025-09-30 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded LNAI yet.
